E-Z-DISK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for E-Z-DISK (E-Z-DISK).
E-Z-DISK is a topical antifungal agent containing micronazole nitrate. Miconazole inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and fungal growth.
| Metabolism | Miconazole is primarily metabolized in the liver via oxidative processes. Systemic absorption after topical application is minimal, but when absorbed, it is metabolized by hepatic microsomal enzymes. |
| Excretion | Primarily renal excretion (unchanged drug and metabolites). Approximately 70% recovered in urine and 30% in feces via biliary excretion. |
| Half-life | Terminal elimination half-life is 8–12 hours in healthy adults, permitting twice-daily dosing. |
| Protein binding | 90% bound primarily to albumin. |
| Volume of Distribution | 0.7 L/kg, indicating distribution into total body water. |
| Bioavailability | Oral: 80% (first-pass metabolism minimal). Topical: 5% (limited systemic absorption). |
| Onset of Action | Oral: 1–2 hours. Topical: within 30 minutes. |
| Duration of Action | Oral: 12 hours; Topical: 6–8 hours (maintains therapeutic levels). |
Not applicable; E-Z-DISK is a device (disk diffusate test for allergy diagnosis), not a therapeutic drug.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required as it is a diagnostic device with no systemic absorption. |
| Liver impairment | No dose adjustment required as it is a diagnostic device with no systemic absorption. |
| Pediatric use | Use per manufacturer instructions; generally not recommended in children under 5 years due to difficulty in interpretation. |
| Geriatric use | No specific adjustments necessary; apply standard precautions for skin testing in elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for E-Z-DISK (E-Z-DISK).
| Breastfeeding | Iodinated contrast agents are excreted into breast milk in low amounts (<0.01% of maternal dose). M/P ratio unknown. Considered compatible; advise temporary cessation for 12-24 hours if concerned. |
| Teratogenic Risk | E-Z-DISK is a radiopaque contrast agent used for diagnostic imaging. No human data; animal studies show no evidence of harm. FDA Category B. Theoretical risk of fetal hypothyroidism if iodine-based. Avoid in 1st trimester unless essential. Minimal to low risk in 2nd and 3rd. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to miconazole nitrate or any component of the formulation"]
| Precautions | ["For external use only","Avoid contact with eyes","Do not use on broken skin","Discontinue if irritation or allergic reaction develops","Use with caution in patients with known hypersensitivity to miconazole or other azole antifungals"] |
Loading safety data…
| Monitor maternal renal function and thyroid status (if iodine-based). Fetal ultrasound may be indicated if radiation dose is high. No specific fetal monitoring required. |
| Fertility Effects | No known effects on fertility in humans. Animal studies show no reproductive impairment. |